In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic process.

The conversation also touches on the potential of artificial intelligence in diagnostics, the prognostic value of genetic mutations, and the importance of considering germline disorders in MDS. This episode is a must-listen for healthcare professionals seeking to deepen their understanding of MDS diagnostics.

Host: Prof Kirsten Grønbæk

Guest: Dr Onima Chowdhury

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this insightful interview with prof. Brian Huntly from the University of Cambridge who tells about his professional journey in hematology as a clinician, scientist and educator.

Listen to prof. Huntly discuss his important contributions to the field of leukemia stem cell biology in the context of current understanding of cell biological hierarchies and leukemia development.

Prof. Huntly also touches on the concepts of early interception and tumor-specific and tumor-nonspecific areas to personalized medicine. Tune in to hear how prof. Huntly combines his work in the fields of science and clinical medicine and what his recommendations are for younger colleagues, who are in the early stages of their careers. 

Host: Isabel Olivera-Martinez, PhD, Medical Writer 

Guest: Prof Brian Huntly

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this podcast, Prof Dame Lesley Fallowfield and Prof Clemens Wendtner discuss patient mental health and communication in the context of Chronic Lymphocytic Leukemia (CLL) treatment. They explore the psychological impact of CLL and leukemia in general, the importance of patient communication, and the need for integrated mental health support. 

The conversation highlights the challenges of explaining complex medical concepts to patients and the role of resilience in both patients and physicians. They also address the challenges of managing patient anxiety and depression, the role of trust in the doctor-patient relationship, the importance of empathy, and the need for integrated psychological support services.

Guests:

Prof Dame Lesley Fallowfield

Prof Clemens Wendtner

Note: This podcast is based on content provided by BeiGene. It has been reviewed by EHA, which found it unbiased and aligned with EHA educational standards, as well as edited by EHA to create an effective educational experience.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with patient advocates Miriam Santos Freire (sickle cell disease) and Loris Brunetta (beta-thalassemia major). Benefit from their experiences as they discuss with our host Isabel Olivera-Martinez the promises and challenges of gene therapy for these conditions.

Listen to their experiences of living with these genetic conditions while they highlight the disparities in treatment access between wealthy and low-income countries. Both view gene therapy as a breakthrough that has the potential to cure these diseases, but express caution regarding its current limitations and complications. Tune in for their valuable insights and recommendations for advancing SCD and thalassemia management.

Host: Isabel Olivera-Martinez, PhD, Medical Writer 

Guests:

Miriam Santos Freire, Patient representative for EuroBloodNet

Patient Advocacy & Communication for Sickle Cell (Portugal & UK) at European Sickle Cell Federation (ESCF)

European Hematology Association (EHA)

ERN-EuroBloodNet

Associação Portuguesa de Pais de Doentes com Hemoglobinopatias (APPDH) – also a Board Member

Loris Brunetta

Board Member of Thalassaemia International Federation (TIF),

Vice-chair of EHA Patients’ Advocacy Committee (PAC),

Member of the Patients and Consumer Working Party (PCWP) at EMA,

EMA expert on ESEC,

Former member of Committee for Orphan Medicinal Products (COMP) at EMA,

ePAG at EuroBloodNet,

Coordinator of the Italian Associations Advocacy Council (IAAC)

President of Associazione Ligure Thalassemici (Italy).

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an interview with Prof Kostas Stamatopoulos, as he shares his personal journey as both a medical doctor and a researcher in hematology and understand how these two activities have always been profoundly linked in his drive to deliver impactful solutions for patients - even though years may pass between a discovery and a change for patients in clinical practice.

Prof Stamatopoulos describes here his work into stereotypy of B-cell receptor (BCR) immunoglobulin and how this phenomenon explains the existence of the same or highly similar subsets of BCR clones in unrelated patients with CLL. Our guest explains further how this knowledge is leading to the classification of CLL patients into subsets with specific pathologies and might help personalize the treatment.

Next to translational research, Prof Stamatopoulos is focusing on patient empowerment. In this podcast, he will explain how he strives to create a more participatory healthcare model, and how he aims to transform education and training for young clinicians and researchers. 

Host: Isabel Olivera-Martinez, PhD, Medical Writer 

Guest: Prof Kostas Stamatopoulos

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

This podcast episode is derived from the MDS Algorithm on EHA Campus. Check out the MDS Algorithm, which is an expert based tool for healthcare providers, ensuring a structured and evidence-based approach to managing myelodysplastic syndromes.

In this episode, our host Prof Kirsten Grønbæk from University of Copenhagen, discusses the management of high-risk MDS with Prof Katharina Götze from Technical University of Munich and Prof Valeria Santini from University of Florence. The experts delve into the two classification systems for MDS, defined by the International Consensus Classification (ICC) and World Health Organization (WHO) in 2022.

They discuss the impact of the similarities and discrepancies between these systems on clinical practice and the patients’ understanding of their disease. The speakers further talk about hypomethylating agents (HMA) as the backbone of current treatments for high-risk MDS. They exchange their views on the considerations for choosing the patients who are most likely to benefit from these treatments, while avoiding myelotoxicity. The experts also discuss selecting the right patients for other (emerging) treatments, such as venetoclax and magrolimab, while stressing that data from phase III trials is yet to become available for some of these agents.

The role of allogeneic transplantation as the only curative option for patients with high-risk MDS is also emphasized, with the experts highlighting the role of Molecular International Prognostic Scoring System (IPSS-M) in selecting the eligible patients. In the closing remarks, the importance and challenges of monitoring the molecular evolution of the disease are stressed, as this technology allows to tailor the available treatments to each individual patient. 

Host: Prof Kirsten Grønbæk

Guests: Prof Katharina Götze & Prof Valeria Santini

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode on recent insights about metabolism of the hematopoietic stem cells (HSCs), Dr Krzysztof Szade from Jagellonian University in Krakow, Poland, discusses HSPc in health, aging and malignancy. This podcast recaps the findings that aim to elucidate the metabolic requirements of HSCs at different stages of aging.

Listen to Dr Szade summarize the data on how heme oxygenase-1 (HO-1) influences glycolytic metabolic stemness of HSCs, impacting on their self-renewal and differentiation. Follow his explanations of the hierarchical relationship between myeloid-biased and balanced HSCs and other observations shedding more light on the mechanisms of HSC aging. As the understanding of the metabolic requirements of HSCs during aging can point to new therapies for hematological disorders, tune in for this latest update.

Guest: Dr Krzysztof Szade

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic.

As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to think about new, adaptive designs that will result in impactful trials in shorter time. Follow Dr Versluis as he explains the different designs and methods that can be used to estimate whether trial will be efficacious or futile before its completion.

The combination of clinical trials with data from existing real-world registries, such as HARMONY or Dutch Cancer Society datasets, may also be an alternative to standard designs. By using examples of trials run by HOVON, the Dutch Hemato-oncology Foundation, Dr Versluis provides additional depth to the discussion. 

Guest: Dr Jurjen Versluis

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same family.

Dr Tawana discusses the discovery of HHMs and provides advice on how to recognize them in clinical practice, which can be hampered by low penetrance and significant differences in disease latency.

Listen to the stories of families affected by HHMs and how the molecular insights gathered from disease evolution in these case studies provide base for improved management of patients in the future. Tune in to hear the recommendations of dr. Tawana on how to optimize testing in clinical pathways and improve outcomes for people with HHMs.

Guest: Dr Kiran Tawana

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients.

Thanks to the clear molecular target (V600E mutation of BRAF), treatment of classical hairy cell leukemia with BRAF inhibitors, such as vemurafenib, is an example of precision oncology that can result in deep responses. As combination of this treatment with anti-CD20 antibody leads to durable complete responses in most patients, Prof Zenz often uses this regime in his patients with refractory or relapsed hairy cell leukemia.

However, as different countries have access to different treatment options, Prof Zenz also discusses the role, sequencing and combinations of other drugs, such as to purine analogs (i.e. cladribine), MEK inhibitors, BTK-inhibitors, Bcl-2 inhibitors (i.e. venetoclax) or recombinant CD22-targeting immunotoxin (i.e. moxetumomab). In light of emerging (although still limited) data on these drugs and questions about their optimal sequencing, guidelines are being developed by Hairy Cell Leukemia Foundation (HCLF) and EHA that aim to help the clinicians with making choices for their patients.

This podcast is further enriched by insights from prof. Enrico Tiacci from University and Hospital of Perugia in Italy, who discovered that V600E mutation of BRAF is the key genetic lesion underlying hairy cell leukemia. Prof Tiacci shares his views on the treatment options and their sequencing, based on the clinical trials he conducted and his clinical experience.

Guest: Prof Thorsten Zenz

This episode is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. This podcast containing accompanying slide content is available as a video on Spotify, YouTube, and EHA Campus. More lectures will be available in the future. Stay tuned!

For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe